Nanotechnology-Based Biosensors in Drug Delivery

A special issue of Biosensors (ISSN 2079-6374). This special issue belongs to the section "Biosensor and Bioelectronic Devices".

Deadline for manuscript submissions: 15 August 2025 | Viewed by 888

Special Issue Editor


E-Mail Website
Guest Editor
Innovation Center for Advanced Technology, Matrix HT, Inc., New York, NY 10019, USA
Interests: biomaterials; cancer nanotechnology; drug delivery; stem cells technology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The integration of nanotechnology with biosensor technology has opened new avenues for enhancing drug delivery systems. As we advance our understanding of nanomaterials and their interactions with biological systems, there is an urgent need to explore and document the innovative applications of nanotechnology-based biosensors in drug delivery. This Special Issue aims to compile cutting-edge research and reviews that highlight the role of nanotechnology-based biosensors in improving the precision, efficacy, and safety of drug delivery methods.

We invite submissions that cover a wide range of topics, including but not limited to the following:

  1. Design and fabrication of nanotechnology-based biosensors for real-time monitoring of drug delivery.
  2. Biosensors for the detection and quantification of drug release in biological systems.
  3. Nanoparticle-based sensing platforms for controlled and sustained drug release.
  4. In vivo applications of nanotechnology-based biosensors for monitoring therapeutic efficacy and safety.
  5. Regulatory challenges and safety assessments of nanotechnology-based drug delivery systems.
  6. Innovative methodologies for integrating biosensors into existing drug delivery frameworks.

Prof. Dr. Hossein Hosseinkhani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biosensors is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biosensor
  • drug delivery
  • nanotechnology
  • biomaterials

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 2067 KiB  
Review
Application of Fluorescence- and Bioluminescence-Based Biosensors in Cancer Drug Discovery
by Tynan Kelly and Xiaolong Yang
Biosensors 2024, 14(12), 570; https://doi.org/10.3390/bios14120570 - 24 Nov 2024
Viewed by 748
Abstract
Recent advances in drug discovery have established biosensors as indispensable tools, particularly valued for their precision, sensitivity, and real-time monitoring capabilities. The review begins with a brief overview of cancer drug discovery, underscoring the pivotal role of biosensors in advancing cancer research. Various [...] Read more.
Recent advances in drug discovery have established biosensors as indispensable tools, particularly valued for their precision, sensitivity, and real-time monitoring capabilities. The review begins with a brief overview of cancer drug discovery, underscoring the pivotal role of biosensors in advancing cancer research. Various types of biosensors employed in cancer drug discovery are then explored, with particular emphasis on fluorescence- and bioluminescence-based technologies such as FRET, TR-FRET, BRET, NanoBRET, and NanoBiT. These biosensors have enabled breakthrough discoveries, including the identification of Celastrol as a novel YAP-TEAD inhibitor through NanoBiT-based screening, and the development of TR-FRET assays that successfully identified Ro-31-8220 as a SMAD4R361H/SMAD3 interaction inducer. The integration of biosensors in high throughput screening and validation for cancer drug compounds is examined, highlighting successful applications such as the development of LATS biosensors that revealed VEGFR as an upstream regulator of the Hippo signaling pathway. Real-time monitoring of cellular responses through biosensors has yielded invaluable insights into cancer cell signaling pathways, as demonstrated by NanoBRET assays detecting RAF dimerization and HiBiT systems monitoring protein degradation dynamics. The review addresses challenges linked to biosensor applications, such as maintaining stability in complex tumor microenvironments and achieving consistent sensitivity in HTS applications. Emerging trends are discussed, including integrating artificial intelligence and advanced nanomaterials for enhanced biosensor performance. In conclusion, this review offers a comprehensive analysis of fluorescence- and bioluminescence-based biosensor applications in the dynamic cancer drug discovery field, presenting quantitative evidence of their impact and highlighting their potential to revolutionize targeted cancer treatments. Full article
(This article belongs to the Special Issue Nanotechnology-Based Biosensors in Drug Delivery)
Show Figures

Figure 1

Back to TopTop